Based on the observations from CTX patients [50,51], Cyp27a1−/− mice [92,93], and goose fatty liver models [94], it is also reasonable to consider Cyp27a1 inhibition for reducing NASH inflammatory responses. The gene discussed is CYP27A1; the disease is metabolic dysfunction-associated steatohepatitis.